广生堂上半年净利亏损6668.81万元，同比增亏

Core Viewpoint - Guangshentang (300436) reported a decline in revenue and net profit for the first half of 2025, indicating challenges in performance and a need for strategic improvements [1] Financial Performance - The company achieved operating revenue of 209 million yuan, a year-on-year decrease of 4.27% [1] - The net profit attributable to shareholders was -66.6881 million yuan, representing a year-on-year decline of 85.05% [1] Strategic Initiatives - The company plans to implement multiple measures to improve performance in the second half of the year [1] - There will be a focus on enhancing the marketing system and diversifying marketing strategies to boost revenue from existing product lines [1] - Guangshentang aims to deepen cooperation with the Zhangzhou health industry chain to actively explore premium traditional Chinese medicine, establishing a second growth driver [1] - The company will optimize supply chain management and continue efforts to reduce costs and increase efficiency [1] - There is a commitment to advancing innovation in research and development, particularly in the field of hepatitis B treatment [1] - The company will explore opportunities for collaboration in innovative drug development and commercialization to support its growth and funding needs [1]